PC 1358

Drug Profile

PC 1358

Alternative Names: Tricomin

Latest Information Update: 22 Oct 2003

Price : $50

At a glance

  • Originator ProCyte Corporation
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alopecia

Most Recent Events

  • 30 Nov 2000 Discontinued - Phase-II for Alopecia in USA (Topical)
  • 11 Jun 1997 Discontinued-Preclinical for Alopecia in Japan (Topical)
  • 21 May 1997 A study has been added to the therapeutic trials section (FDC Reports 1997 May)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top